Please use this identifier to cite or link to this item: https://rima.ufrrj.br/jspui/handle/20.500.14407/10110
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCaminotto, Eriane de Lima
dc.date.accessioned2023-12-21T18:57:41Z-
dc.date.available2023-12-21T18:57:41Z-
dc.date.issued2015-10-21
dc.identifier.citationCAMINOTTO, Eriane de Lima. Influência de fármacos no sistema-renina-angiotensina do globo ocular de cães hígidos: desenvolvimento farmacotécnico e avaliação clínica. 2015. [52 f.]. Tese( PROGRAMA DE PÓS-GRADUAÇÃO EM MEDICINA VETERINÁRIA (PATOLOGIA E CIÊNCIAS CLÍNICAS)) - Universidade Federal Rural do Rio de Janeiro, [Seropédica-RJ] .por
dc.identifier.urihttps://rima.ufrrj.br/jspui/handle/20.500.14407/10110-
dc.description.abstractO glaucoma é uma das doenças que mais causa cegueira em cães e não possui cura, apenas tratamento. A dificuldade na drenagem do humor aquoso (HA) resulta no aumento da pressão intra-ocular (PIO) que representa um fator de risco significativo para a ocorrência dessa afecção, conduzindo à danos irreversíveis como a perda progressiva do campo visual e da visão como um todo, morte das células ganglionares da retina (CGR), perda de axônios do nervo óptico e escavação do mesmo. Além deste, diversos mecanismos podem contribuir para o desenvolvimento e progressão desta doença como, por exemplo, os desequilíbrios do sistema-renina-angiotensina (SRA) e as doenças cardiovasculares e renais. A mensuração da PIO e o exame do fundo de olho são os métodos mais utilizados para diagnosticar essa afecção. O tratamento de escolha se baseia em colírios que estimulam a drenagem do HA e/ou diminuam sua produção resultando no controle da PIO; porém em muitos casos a terapia não atinge o efeito desejado e culmina em cegueira. Na tentativa de mudar essa perspectiva terapêutica, o presente trabalho comparou, em cães sadios e normotensos da raça Beagle, a ação sistêmica e ocular de três fármacos: maleato de timolol 0,5% (beta-bloqueador não seletivo usado nos casos de glaucoma), captopril 0,1% e 0,5% (inibidor de ECA1 nunca antes estudado nesta maior concentração em cães) e aceturato de diminazeno – DIZE 0,1% e 0,5% (ativador endógeno de ECA2, nunca antes pesquisado em olhos caninos). Os dois últimos fármacos foram formulados para uso oftalmológico visando a redução da PIO, uma vez que é sabido sobre a existência do SRA a nível ocular e que os mesmos já foram administrados sistemicamente com sucesso na redução pressão arterial sistêmica (PAS). Dessa forma, antes e após os tratamentos, 18 cães foram submetidos ao teste lacrimal de Schirmer (TLS1) e à coleta sanguínea para dosagem da concentração da enzima conversora de angiotensina (ECA 1) do soro.Durante três dias consecutivos antes dos tratamentos e em três horários distintos (6h, 12h, e 18h) todos os animaispassaram por quatro exames, seguindo sempre a mesma ordem: avaliação do diâmetro pupilar, aferição da PIO, aferição da FC e da PAS.Após a obtenção dos valores normais, os animais tiveram o olho esquerdo submetido aos protocolos pré-determinados inicialmente com 1 gota, a cada 12 horas, por 7 dias na menor concentração e, nos demais 7 dias, na maior concentração. Os olhos adelfos foram o controle e, todos os dias nos três horários distintos os cães passaram pelos mesmos exames iniciais. Todos os fármacos tiveram boa penetrabilidade e ausência de efeitos adversos a nível ocular. Quanto à produção lacrimal, o captopril é o mais indicado para os pacientes glaucomatosos e portadores de ceratoconjuntivite seca, enquanto que o timolol é contra-indicado para os mesmos. Todos diminuíram os valores da PIO, sendo que na segunda semana de tratamento, com concentrações maiores, as reduções foram mais significativas. A bradicardia foi observada nos animais tratados com captopril 0,5%, com uma redução de quase 9% na FC, quando comparado com o captopril em menor concentração.por
dc.description.sponsorshipFundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do RJ - FAPERJpor
dc.formatapplication/pdf*
dc.languageporpor
dc.publisherUniversidade Federal Rural do Rio de Janeiropor
dc.rightsAcesso Abertopor
dc.subjectsystem renin-angiotensin-aldosteroneeng
dc.subjectdogseng
dc.subjectglaucomapor
dc.subjectsistema renina angiotensinapor
dc.subjectcãespor
dc.titleInfluência de fármacos no sistema-renina-angiotensina do globo ocular de cães hígidos: desenvolvimento farmacotécnico e avaliação clínicapor
dc.title.alternativeInfluence of drugs on the renin-angiotensin system of the ocular globe of healthy dogs: pharmacotechnical development and clinical evaluationeng
dc.typeTesepor
dc.description.abstractOtherGlaucoma is a disease that causes more blindness in dogs and has no cure, only treatment. The difficulty in the drainage of aqueous humor (AH) results in an increase in intraocular pressure (IOP), representing a significant risk factor for the occurrence of this condition, leading to irreversible damage to the progressive loss of visual field and vision as a whole death of retinal ganglion cells (RGC), loss of axons in the optic nerve and excavation of the same. In addition to this, several mechanisms may contribute to the development and progression of this disease, for example, unbalances of the renin-angiotensin-system (RAS), and cardiovascular and renal diseases. The measurement of IOP and the examination of the fundus are the methods used to diagnose this condition. The treatment of choice is based on eye drops that stimulate drainage of HA and / or decrease their production resulting in IOP control; however in many cases the treatment does not attain the desired effect, culminating in blindness. In an attempt to change this therapeutic perspective, this study compared, in healthy and normotensive Beagle dogs, systemic and ocular action of three drugs: timolol maleate 0.5% (non-selective beta-blocker used in cases of glaucoma) , captopril 0.1% and 0.5% (ECA1 inhibitor never before studied in greater concentration in dogs) and aceturato of diminazene - DIZE 0.1% and 0.5% (endogenous activator of ACE2, never before researched in eyes canines). The latter two drugs were formulated for ophthalmic use for the reduction of IOP, since it is known about the existence of SARS eye level, and that they have been successfully administered systemically at reducing systemic arterial pressure (SAP). Thus, before and after treatment, 18 dogs underwent the Schirmer Tear Test (TLS1) and blood collection for measuring the concentration of angiotensin-converting enzyme (ECA1) serum. For three consecutive days before treatment and at three times (6h, 12h and 18h) all animals have gone through four exams, always following the same order: evaluation of pupil size, IOP measurement, measurement of HR and SAP. After obtaining the normal range, the animals had the left eye subjected to predetermined protocols initially with 1 drop every 12 hours, 7 days a lower concentration and, in the other seven days, in the highest concentration. The adelfos eyes were control and every day in the three different times dogs went through the same initial exams. All drugs were good penetration and no adverse eye level. As for tear production, captopril is the most suitable for glaucoma patients and patients with keratoconjunctivitis sicca, while timolol is contraindicated for them. All decreased IOP values, and in the second week of treatment, with higher concentrations, reductions were more significant. The bradycardia was observed in captopril-treated animals 0.5%, with a reduction of almost 9% in HR compared to captopril in lower concentrationseng
dc.contributor.advisor1Reis, Luis Carlos
dc.contributor.advisor1ID48425257700por
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/2679836949147357por
dc.contributor.referee1Pigatto, João Antonio Tadeu
dc.contributor.referee2Fonseca, Fabrícia Viana
dc.contributor.referee3Côrtes, Wellington da Silva
dc.contributor.referee4Paiva, Jonimar Pereira
dc.creator.ID31076598862por
dc.creator.Latteshttp://lattes.cnpq.br/7255374591419563por
dc.publisher.countryBrasilpor
dc.publisher.departmentInstituto de Veterináriapor
dc.publisher.initialsUFRRJpor
dc.publisher.programPrograma de Pós-Graduação em Medicina Veterinária (Patologia e Ciências Clínicas)por
dc.relation.referencesABRAMS, K.L. Medical and surgical management of the glaucoma patient. Clinical Technical Small Animal Practice, v.16, p.71-76, 2001. ABRAMS, K.L.; BROOKS, D.E.; LARATTA, L.J.; BARNHILL, M.A.; FRAZIER, D. Angiotensin converting enzyme system in the normal canine eye: pharmacological and physiological aspects. Journal of Ocular Pharmacology and Therapeutics, v.1, p. 41-51, 1991. ADAMS, H.R. Farmacologia e Terapêutica em Veterinária. 8 ed. Rio de Janeiro: Guanabara&Koogan, 2001. 1034 p. AGUILERA, G; KISS A. Regulation of the hypothalamic-pituitary-adrenal axis and vasopressin secretion. Role of angiotensin II. Advances in Experimental Medicine and Biology, v.396, p.105–12, 1996. BATISTUZZO, J.A.O.; ETO, Y.; ITAYA, M. Formulário Médico Farmacêutico. 4 ed. Editora Pharmabooks, 2011. 65-76p. BERKA, J.L.; STUBBS, A.J.; WANG, D.Z. Renin-containing Müller cells of the retina display endocrine features. Investigative Ophthalmology & Visual Science, v.36, p.1450–1458, 1995. BONOMI, L.; ZAVARISE, G.; NOYA, E.; MICHIELETTO, S. Effects of timolol maleate on tear flow in human eyes. Albrecht Von Graefes Arch Klin Exp Ophthalmol. v.1, p.19-22, 1980. BOROVIC, D.; BENDELIC, E.; CHISELIŢĂ, D. Study of kini-kallikrein and renin-angiotensin systems in patients with primary open angle glaucoma. Oftalmologia, v.53, n.2, p.61-68, 2009. BROOKS, D.E.; GARCIA, G.A.; DREYER, E.B.; ZURAKOWSKI, D.; FRANCO-BOURLAND, R.E. Vitreous body glutamate concentration in dogs with glaucoma. American Journal of Veterinary Research, v.58, p.864-867, 1997. CABRAL, R.R.; CIASCA, B.D.; OLIVEIRA, V.M.C.; VAZ-CURADO, A.P.; LARSSON, M.H.M.A. Valores da pressão arterial em cães pelos métodos oscilométrico e Doppler vascular. Arquivo Brasileiro de Medicina Veterinária e Zootecnia, v.62, n.1, 2010. CHIOU, H.J. et al. Evaluation of ocular arterial changes in glaucoma with color Doppler ultrasonography. Journal Ultrasound in Medicine, v.18, p.295-302, 1999. CONSTAD, W.H.; FIORE, P.; SAMSON, C.; CINOTTI, A.A. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. American Journal of Ophthalmology, v.105, p.674-677, 1988. 40 CRAWFORD, K.; KAUFMAN, P.L. Pilocarpine antagonizes prostaglandin F2α-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2α. Archives of ophthalmology, v.105, p.1112–1116, 1987. CULMAN, J.; HOHLE, S.; QADRI, F.; EDLING, O.; BLUME, A.; LEBRUN, C.; UNGER, T. Angiotensin as neuromodulator/neurotransmitter in central control of body fluid and electrolyte homeostasis. Clinical and Experimental Hypertension, v.17, p.281–293, 1995. CUNHA-VAZ, J. The blood-ocular barriers. Survey of Ophthalmology, v.23, p.279–296, 1979. CUNHA-VAZ, J.G. The blood-retinal barrier system. Basic concepts and clinical evaluation. Experimental Eye Research, v.78, p.715-721, 2004. DANSER, A.H.J.; DERKX, F.H.M.; ADMIRAAL, P.J.J.; DEINUM, J.; DE JONG, P.T.V.M.; SCHALEKAMP, M.A.D.H. Angiotensin levels in the eye. Investigative Ophthalmology & Visual Science, v.35, p.:1008–1018, 1994. DE GASPARO, M.; CATT, K.J.; INAGAMI, T.; WRIGHT, J.W.; UNGER, T. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacology Reviews, v.52, p.415-472, 2000. DYCE, K. M.; WENSING, C. J. G.; SACK, W. O. Tratado de Anatomia Veterinária. 3 ed. São Paulo: Elsevier Brasil, 2004. 813 p. DONOGHUE, M.; HSIEH, F.; BARONAS, E.; GODBOUT, K.; GOSSELIN, M.; STAGLIANO, N.; DONOVAN, M.; WOOLF, B.; ROBISON, K.; JEYASEELAN, R.; BREITBART, R.E.; ACTON, S. A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation research. v.87, p.1-9, 2000. FELDMAN, R.M. Conjuntival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. Journal of Ocular Pharmacology and Therapeutics, New York, v.19, n.1, p.23-31, 2003. FOUREAUX, G.; NOGUEIRA, J.C.; NOGUEIRA, B.S.; FULGÊNCIO, G.O.; MENEZES, G.B.; FERNANDES, S.O.; CARDOSO, V.N.; FERNANDES, R.S.; OLIVEIRA, G.P.; FRANCA, J.R.; FARACO, A.A.; RAIZADA, M.K.; FERREIRA, A.J. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Investigative Ophthalmology & Visual Science, v.6, p.4296-4306, 2015. GELATT, K.N.; BROOKS, D.E. The canine glaucomas. In:______. Veterinary ophthalmology. 3.ed. Malvern: Lea & Febiger, cap.21, p.701-754, 1999. GIESE, M.J.; SPETH, R.C. The ocular renin–angiotensin system: A therapeutic target for the treatment of ocular disease. Pharmacology & Therapeutics. p.1-22, 2013. 41 GIONFRIDDO, J.R. Recognizing and managing acute and chronic cases of glaucoma. Veterinary Medicine, v.90, p.265-275, 1995. GOODMAN & GILMAN. As bases farmacológicas da terapêutica. 12. ed. Porto Alegre: AMGH, 2012. 2112 p. GYTON, A.C.; HALL, J.E. Tratado de Fisiología Médica. 10 ed. McGraw-Hill Interamericana de España, 2001. 695-699 p. HAKANSON, N.; DRU FORRESTER, S. Uveitis in the dog and cat. Veterinary Clinics of North America Small Animal Practice, v.20, n.3, p.715-735, 1990. HIROOKA, K.; SHIRAGA, F. Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma. Clinical Ophthalmology. v.3, p. 217–223, 2007. HOY, Y.; DELAMERE, N.A. Influence of ANG II on cytoplasmic sodium in cultured rabbit nonpigmented ciliary epithelium. American Journal of Physiology - Cell Physiology, v.283, p.552–559, 2002. IUSUF, D.; HENNING, R.H.; VAN GILST, W.H.; ROKS, A.J. Angiotensin-(1-7): Pharmacological properties and pharmacotherapeutic perspectives. European Journal of Pharmacology. v.13, p.303-312, 2008. ITO, M.; OLIVERIO, M.I.; MANNON, P.J. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proceedings of the National Academy of Sciences of the United States of America, v.92, p.3521–3525, 1995. JACKSON, K.E. Renin and Angiotensin. In: Goodman & Gilman`s The pharmacological basis of therapeutics. 11 ed. New York: Medical Publishing Division, 2006. 789-814p. JEGOU, J.P. Lês glaucomes. Recueil de Médecine Vétérinaire, v.165, p.263-278, 1989. KAZUYUKI, H.; FUMIO, S. Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma. Clinical Ophthalmology, v.3, p.217-223, 2007. KHAN, N.; KHALEQUE, M.A.; ISLAM, M.S.; BEGUM, R.A.; UDDIN, M.S.; HOSSAIN, M.M.; ALI M. Effect of topical Beta blocker (Timolol maleate 0.5%) in primary open angle glaucoma. Mymensingh Medical Journal, v.4, p.648-653, 2012. KOSTENIS, E.; MILLIGAN, G.; CHRISTOPOULOS, A.; SANCHEZ-FERRER, C.F.; HERINGER-WALTHER, S.; SEXTON, P.M.; GEMBARDT, F.; KELLETT, E.; MARTINI, L.; VANDERHEYDEN, P.; SCHULTHEISS, H.P.; WALTHER, T. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation, v.14, p.1806-1813, 2005. KUNER, A.; VIEIRA, J.B.; CAVALCANTI, P.D.C.; FALEIRO, R.D. Retrospective study (2010-2013) of the incidence of keratoconjunctivitis sicca (KCS) in dogs with glaucoma. Veterinary Ophthalmology, v.16, p.4121-425, 2013. 42 KWON, Y.H.; CAPRIOLI, J. Primary open angle glaucoma. In: Duane`s Ophthalmology. CD-ROM ed. Lippincot Williams et Wilkins, 2006, v.3, 45p. LEMOS, V.S.; SILVA, D.M.; WALTHER, T.; ALENINA, N.; BADER, M.; SANTOS, R.A. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of masknockout mice. Journal Cardiovascular Pharmacology, v. 46, p. 274-279, 2005. LUHTALA, S.; VAAJANEN, A.; OKSALA, O.; VALJAKKA, J.; VAPAATALO, H. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. Journal of Ocular Pharmacology and Therapeutics, v.25, n.1, p.23-28, 2009. MALEATO DE TIMOLOL. Responsável técnico Elizabeth Mesquita. São Paulo: Allergan Produtos Farmacêuticos LTDA, 2013. Bula de remédio. MARTINS, B.C.; VICENTI, F.A.M.; LAUS, J.L. Síndrome glaucomatosa em cães – Parte 1. Ciência Rural, v.36, n.6, 2006. MEHTA, A.; IYER, L.; PARMAR, S.; SHAH, G.; GOYAL, R. Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Canadian Journal of Physiology and Pharmacology, v.88, n.5, p.595-600, 2010. MITCHELL, P.; LEE, A.J.; ROCHTCINA, E.; WANG, J.J. Open-angle glaucoma and systemic hypertension: The Blue Mountains Eye Study. Journal Glaucoma, v.13, p.319-326, 2004. MUÑOZ-NEGRETE, F.J.; PÉREZ-LÓPEZ, M.; WON KIM, H.R.; REBOLLEDA, G. Nuevos desarrollos en el tratamiento médico del glaucoma. Archivos de la Sociedad Española de Oftalmología, n.10, v.84, p.491-500, 2009. NASKAR, R.; DREYER, E. New horizons in neuroprotection. Survey of Ophthalmology, v.5, supl.3, p.S250-S255, 2001. ORIÁ, A. P. Considerations abaout etectroretinography in dogs. Ciência Rural, v. 34, p. 323-328, 2004. PLUMMER, C.E.; MACKAY, E.O.; GELATT, K.N. Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs. Veterinary Ophthalmology. v.9, n.4, p.245-249, 2006. PRATT, N.L.; RAMSAY, E.N.; ELLETT, L.M.K.; NGUYEN, T.A.; ROUGHEAD, E.E. Association between Ophthalmic Timolol and Hospitalisation for Bradycardia. Journal of Ophthalmology, p.387-393, 2015. QUIROZ Mercado, Joaquín, Curso De Actualización En Oftalmología Em Perros Y Gatos, Universidad Michoacana de San Nicolás de Hidalgo, México, 2007. 43 RAMIREZ, M.; DAVIDSON, E.A.; LUTTENAUER, L.; ELENA, P.P.; CUMIN, F.; MATHIS, G.A.; DE GASPARO, M. The renin-angiotensin system in the rabbit eye. Journal of Ocular Pharmacology and Therapeutics, v.12, n.3, p.299-312, 1996. REINSTEIN, S.L.; RANKIN, A.J.; ALLBAUGH, R. Canine glaucoma: phatophysiology and diagnosis. Compendium: Continuing Education for Vetinarians. v.31, n.10, p.450-452, 2009. RIBEIRO, A.P.; MARTINS, B.C.; LAUS, J.L. Síndrome glaucomatosa em cães – parte 2. Ciência. Rural, v.37, n.6, 2007. ROBINSON, C.C.; ALLBAUGH, R.A.; RAMIREZ, A.; JEANS, J.K.; WHITLEY, R.D.; BEN-SHLOMO, G.; ELLINWOOD, N.M. The effect of topical 0,5% timolol maleate ophthalmic solutionon canine tears. Veterinary Ophthalmology, v.16, p.413-416, 2013. SAGARA, T. ; GATON, D.D. ; LINDSEY, J.D. ; GABELT, B.T. ; KAUFMAN, P.L. ; WEINREB, R.N. Topical prostaglandin F2alpha treatment reduces collagen types I,II,II and IV in the monkey uveoscleral outflow pathway. Archives of Ophthalmology, Chicago, v.117, n.6, p.794-801, 1999. SANTOS, R.A.; SIMOES E SILVA, A.C.; MARIC, C.; SILVA, D.M.; MACHADO, R.P.; DE BUHR, I. Angiotensin (1-7) is an endogenous ligand for the G-protein-coupled receptor Mas. Proceedings of the National Academy of Sciences of the United States of America, v.8, p.8258-8263, 2003. SLATTER, D. Glaucoma. In:______. Fundamentals of veterinary ophthalmology. 2.ed. Philadelphia:Saunders, p.338-364, 1990. SLATTER, D. Fundamentos De Oftalmología Veterinaria, 3ª Edición, Editorial. Inter-Médica, Buenos Aires, Argentina, p. 390-450, 2004. SLATTER, D. Tratado de Cirugía en pequeños animales, Tercera Edición, Tomo 2, Editorial Inter-Médica, Argentina, p. 1671-1697, 2005. SOLTAU, J.B.; ZIMMERMAN, T.J. Changing paradigms in the medical treatment of glaucoma. Survey in Ophthalmology, New York, v.47, Suppl 1, p.s2-5, 2002. SU, J.B. Kinins and cardiovascular diseases. Current Pharmceutical Design, v.12, p.3423-3435, 2006. TAKIYAMA, N.; SHOJI, S.; HABATA, I.; OHBA, S. The effects of a timolol maleate gel-forming solution on normotensive Beagle dogs. Journal of Veterinary Medical Science, v.6, p.631-633, 2006. TAMBURRELLI, C. Ultrasonographic evaluation of optic disc swelling: comparison with cslo in idiopathic intracranial hypertension. Investigative Ophthalmology & Visual Science, v.41, p.2960–2966, 2000. 44 TIELSCH, J.M.; KATZ, J.; SOMMER, A.; QUIQLEY, H.A.; JAVITT, J.C. Hypertension, perfusion pressure, and primary open angle glaucoma. A population-based assessment. Archives of Ophthalmology. v.113, p.216-221, 1995. TIKELLIS, C.; BERNARDI, S.; BURNS, W.C. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Current Opinion in Nephrology and Hypertension, v.1, p.62-68, 2011. VAAJANEN, A.; VAPAATALO, H.; KAUTIAINEN, H.; OKSALA, O. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Investigative Ophthalmology & Visual Science. v.6, p.2557-62, 2014. VAAJANEN, A.; VAPAATALO, H. Local Ocular Renin-Angiotensin System – A target for Glaucoma Therapy? Basic & Clinical Pharmacology & Toxicology, v.109, p.217-224, 2011. VAAJANEN, A. Expression and function of angiotensins in the regulation of intraocular pressure. Thesis. University of Helsinki, 2009. VAAJANEN, A.; LUHTALA, S.; OKSALA, O.; VAPAATALO, H. Does the renin-angiotensin system also regulate intra-ocular pressure? Annals of Medicine, v.40, p.418–427, 2008. VICKERS, C.; HALES, P.; KAUSHIK, V.; DICK, L.; GAVIN, J.; TANG, J.; GODBOUT, K.; PARSONS, T.; BARONAS, E.; HSIEH, F.; ACTON, S.; PATANE, M.; NICHOLS, A.; TUMMINO, P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. Journal of Biology Chemistry. v.277, p.14838-14843, 2002. WAGNER, J.; JAN DANSER, A.H.; DERKX, F.H. Demonstration of rennin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular rennin-angiotensin system. British Journal of Ophthalmology, v.80, p.159–163, 1996. WANG, R.F.; PODOS, S.M.; MITTAG, T.W.; YOKOYOMA, T. Effect of CS- 088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Experimental Eye Research, v. 80, p.629-632, 2005. WATKINS, R.W.; BAUM, T.; CEDENO, K.; SMITH, E.M.; YUEN, P.H.; AHN, H.S.; BARNETT, A. Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits. Journal of Ocular Pharmacology and Therapeutics, v.3, n.4, p.295-307, 1987. WEITZMAN, M.; CAPRIOLI, J. Medical Terapy of glaucoma. In: Tasman W, Jaeger EA (eds). Duanes´s Ophthalmology on CD-ROM. v.3, Chapter 56. Pippincot Williams et Wilkins. Philadelphia, 2006. WHITEMAN, A.L. ; KLAUSS, G.; MILLER, P.E.; DUBIELZIG, R.R. Morphologic features of degeneration and cell death in the neurosensory retina in dogs with primary angle-closure glaucoma. American Journal of Veterinary Research, v.63, p.257-261, 2002. WILKIE, D.A. Glaucoma. In: BIRCHARD, S.J.; SHERDING, R.G. Manual Saunders – clínica de pequenos animais. São Paulo: Roca, p.1360-1366, 1998. WILLIS, A.M. Ocular hypotensive drugs. Veterinary Clinics of North America: Small Animal Practice, Philadelphia, v.34, n.3, p.755-76, 2004. WOOD, J.L.N.; LAKHANI, K.H.; MASON, I.K.; BARNETT, K.C. Relationship of the degree of goniodysgenesis and other ocular measurements to glaucoma in great danes. American Journal of Veterinary Research, v.62, p.1493–1499, 2001.por
dc.subject.cnpqMedicina Veterináriapor
dc.thumbnail.urlhttps://tede.ufrrj.br/retrieve/4856/2015%20-%20Eriane%20de%20Lima%20Caminotto.pdf.jpg*
dc.thumbnail.urlhttps://tede.ufrrj.br/retrieve/19490/2015%20-%20Eriane%20de%20Lima%20Caminotto.pdf.jpg*
dc.thumbnail.urlhttps://tede.ufrrj.br/retrieve/25831/2015%20-%20Eriane%20de%20Lima%20Caminotto.pdf.jpg*
dc.thumbnail.urlhttps://tede.ufrrj.br/retrieve/32254/2015%20-%20Eriane%20de%20Lima%20Caminotto.pdf.jpg*
dc.thumbnail.urlhttps://tede.ufrrj.br/retrieve/38684/2015%20-%20Eriane%20de%20Lima%20Caminotto.pdf.jpg*
dc.thumbnail.urlhttps://tede.ufrrj.br/retrieve/45062/2015%20-%20Eriane%20de%20Lima%20Caminotto.pdf.jpg*
dc.thumbnail.urlhttps://tede.ufrrj.br/retrieve/51438/2015%20-%20Eriane%20de%20Lima%20Caminotto.pdf.jpg*
dc.thumbnail.urlhttps://tede.ufrrj.br/retrieve/57896/2015%20-%20Eriane%20de%20Lima%20Caminotto.pdf.jpg*
dc.originais.urihttps://tede.ufrrj.br/jspui/handle/jspui/1390
dc.originais.provenanceSubmitted by Sandra Pereira (srpereira@ufrrj.br) on 2017-01-24T16:23:42Z No. of bitstreams: 1 2015 - Eriane de Lima Caminotto.pdf: 1339748 bytes, checksum: 753de2c181b04ca05748c103c2d6ec8b (MD5)eng
dc.originais.provenanceMade available in DSpace on 2017-01-24T16:23:42Z (GMT). No. of bitstreams: 1 2015 - Eriane de Lima Caminotto.pdf: 1339748 bytes, checksum: 753de2c181b04ca05748c103c2d6ec8b (MD5) Previous issue date: 2015-10-21eng
Appears in Collections:Doutorado em Medicina Veterinária (Patologia e Ciências Clínicas)

Se for cadastrado no RIMA, poderá receber informações por email.
Se ainda não tem uma conta, cadastre-se aqui!

Files in This Item:
File Description SizeFormat 
2015 - Eriane de Lima Caminotto.pdfDocumento principal1.31 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.